Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 153

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 153
---
 ability to continue as a going concern. There can be no assurance that these funds will be available, or if they are available, their availability will be on terms acceptable to the Company or in an amount sufficient to enable the Company to fully complete its development activities, sustain operations or pay back its debt. NLS believes that its current cash on hand and access to existing financing arrangements will not be sufficient to fund its projected operating requirements for a period of one year from the issuance of the financial statements included elsewhere in this proxy statement/prospectus. This raises substantial doubt about its ability to continue as a going concern. NLS expects that NLS will be required to obtain additional liquidity in order to fund its operations through the approval of its lead product candidate. Until NLS can generate significant revenues, if ever, NLS expects to satisfy its future cash needs through debt, equity financing or income from a partnership deal. NLS cannot be certain that funding will be available to it on acceptable terms, if at all. If funds are not available, NLS may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to its products. NLS may ultimately be forced to file for bankruptcy if no funds are available either through a financing or a strategic partnership. Until NLS can generate significant revenues, if ever, NLS expects to satisfy its future cash needs through debt or equity financing. NLS cannot be certain that additional funding will be available to it on acceptable terms, if at all. NLS believes that its current cash on hand and access to existing financial arrangements will not be sufficient to fund its projected operating requirements for at least one year from the issuance of the financial statements included elsewhere in this proxy statement/prospectus. If funds are not available, NLS may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to its products. 40 NLS has a limited operating history, has incurred significant operating losses since its inception, and anticipates that it will incur continued losses for the foreseeable future. NLS is an emerging biopharmaceutical company with a limited operating history. To date, NLS has focused almost exclusively on developing product candidates using the active ingredient mazindol in proprietary formulations. NLS has funded its operations to date primarily through proceeds from the private placement of NLS Common Shares, convertible instruments, related party credit facilities, shareholder loans, an initial public offering of NLS Common Shares and Warrants